2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 22:29, 22 October 2023
, 22 October 2023no edit summary
No edit summary |
|||
| Line 153: | Line 153: | ||
* admission was safe and well-tolerated | * admission was safe and well-tolerated | ||
|- | |- | ||
|Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women | |Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women {{#pmid:33888596|pmid338885960}} | ||
|[[RCT]], 10 weeks | |[[RCT]], 10 weeks | ||
* placebo (n=12) | * placebo (n=12) | ||